Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 6,350 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intestinal Disorders Clear all
Completed No phase listed Observational

A Screening Study Targeting Tumor-specific Antigens

NCT05158621
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
Interventions
blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
Procedure
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • East Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 19, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

NCT02544152
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Huntsville, Alabama • North Little Rock, Arkansas • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 19, 2026, 5:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

NCT03555149
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Regorafenib, Atezolizumab, Imprime PGG, Bevacizumab, Isatuximab, Selicrelumab, Idasanutlin, AB928, LOAd703
Drug · Genetic
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 19, 2026, 5:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cell Transplantation in Crohn's Disease

NCT04224558
View directory record Official record
Conditions
Crohn Disease
Interventions
Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
Drug · Procedure · Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years to 28 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 19, 2026, 5:23 PM EDT
Completed No phase listed Observational

PET Respiratory Gating to Detect Hepatic Metastasis in Patients With Colon Cancer

NCT01401309
View directory record Official record
Conditions
Colon Cancer
Interventions
Not listed
Lead sponsor
Southwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 21, 2014 · Synced Oct 19, 2026, 5:23 PM EDT
Recruiting Not applicable Interventional

Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer

NCT05789433
View directory record Official record
Conditions
Colonic Neoplasms, Rectal Neoplasms
Interventions
Aerobic exercise, Progressive stretching
Behavioral
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 19, 2026, 5:23 PM EDT
Recruiting Phase 3 Interventional

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT07499232
View directory record Official record
Conditions
Crohn Disease
Interventions
Guselkumab, Risankizumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
39
States / cities
Dothan, Alabama • Mobile, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

NCT02317549
View directory record Official record
Conditions
Septic Shock
Interventions
LB1148, Placebo
Drug
Lead sponsor
Leading BioSciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Acceptability and Efficacy of Zemedy App Versus Education and Relaxation Training App for IBS

NCT04665271
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Zemedy App
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude

NCT04111263
View directory record Official record
Conditions
Gastrointestinal Injury, Acute Mountain Sickness
Interventions
FP, Placebo, High altitude, Sea level
Dietary Supplement · Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
17 Years to 39 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 19, 2026, 5:23 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

NCT06456593
View directory record Official record
Conditions
Moderately to Severely Active Crohn Disease
Interventions
Obefazimod, Placebo
Drug · Other
Lead sponsor
Abivax S.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Sun City, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease

NCT00102921
View directory record Official record
Conditions
Crohn Disease
Interventions
CCX282-B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
14
States / cities
Los Angeles, California • Golden, Colorado • Littleton, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Transcutaneous VNS to Treat Pediatric IBD

NCT03863704
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03398148
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
risankizumab IV, placebo for risankizumab, risankizumab SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
82
States / cities
Coronado, California • Irvine, California • La Jolla, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Not applicable Interventional

Behavioral Weight Loss Program for Cancer Survivors in Maryland

NCT04534309
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Melanoma (Skin), Endometrial Cancer, Gallbladder Cancer, Rectal Cancer, Kidney Cancer, Bladder Cancer
Interventions
Written Weight Loss Material, Weight Loss App, Behavioral Lifestyle Weight Loss Intervention (Coaching)
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Flat Polyp Detection Using New Narrow Band Imaging (NBI) Compared to White Light Colonoscopy - The FIND FLAT Colonoscopy Study

NCT01310699
View directory record Official record
Conditions
Colorectal Neoplasms, Colonic Polyps, Colorectal Cancer
Interventions
Olympus Colonoscope CFHQ190AL
Device
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
3
States / cities
Palo Alto, California • San Francisco, California • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 19, 2026, 5:23 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

NCT05700916
View directory record Official record
Conditions
Dyslipidemias, Obesity
Interventions
Milk Polar Lipid-Rich Dairy Powder, Dairy Powder
Drug · Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 19, 2026, 5:23 PM EDT
Withdrawn Phase 1 Interventional

A Study of Guselkumab in Adult Participants With Celiac Disease

NCT04704843
View directory record Official record
Conditions
Celiac Disease
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Lancaster, California • Chesterfield, Michigan • Wyoming, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 5:23 PM EDT
Recruiting Phase 2 Interventional

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07845487
View directory record Official record
Conditions
Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
Interventions
PALI-2108, Placebo
Drug
Lead sponsor
Palisade Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Sun City, Arizona • San Diego, California • Bristol, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 5:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Assessing the Gut Microbiome and Its Association With Pediatric Stress and Cognition

NCT06269614
View directory record Official record
Conditions
Autism Spectrum Disorder, Adverse Childhood Experiences, Stress Reaction
Interventions
Probiotic
Dietary Supplement
Lead sponsor
Nova Southeastern University
Other
Eligibility
4 Years to 95 Months
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 19, 2026, 5:23 PM EDT
Completed No phase listed Observational

Utility of PET In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases

NCT00588549
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2009 · Synced Oct 19, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

Palliative Management of Inoperable Malignant Bowel Obstruction

NCT04027348
View directory record Official record
Conditions
Malignant Bowel Obstruction
Interventions
Dexamethasone, Metoclopramide, Octreotide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 19, 2026, 5:23 PM EDT
Terminated Phase 3 Interventional Results available

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

NCT03467958
View directory record Official record
Conditions
Crohn Disease
Interventions
Ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
190
States / cities
Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 142 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 19, 2026, 5:23 PM EDT
Completed Phase 2 Interventional

CP-461 for the Treatment of Crohn's Disease

NCT00042055
View directory record Official record
Conditions
Crohn's Disease
Interventions
CP-461
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 19, 2026, 5:23 PM EDT